SION (Sionna Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics OCF Margin %?

Sionna Therapeutics SION +5.64% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Sionna Therapeutics ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Sionna Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-21.84 Mil. Sionna Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Sionna Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Sionna Therapeutics's current OCF Yield % is -3.62%.

The historical rank and industry rank for Sionna Therapeutics's OCF Margin % or its related term are showing as below:


SION's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Sionna Therapeutics OCF Margin % Related Terms

Sionna Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics OCF Margin % Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SION
12GF Score
Sionna Therapeutics Inc SION
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Sionna Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-66.297/0
= %

Sionna Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-21.84/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Sionna Therapeutics (SION) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sionna Therapeutics and its competitors. According to the industry distribution chart, Sionna Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry.
Is Sionna Therapeutics' OCF Margin % too high?
Sionna Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Sionna Therapeutics ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' OCF Margin % compare to TYRA and RAPP?
According to the Biotechnology industry distribution chart, Sionna Therapeutics ranks #999999 out of 954 companies for OCF Margin %. This places Sionna Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sionna Therapeutics and its competitors. Sionna Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price